Clinical trial · Observational
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a local, prospective, non-interventional, non-controlled, multicenter, observational study (regulatory postmarketing surveillance). Each physician will enroll patients who have received at least 1 dose of Yervoy, and each patient will be followed for up to 12 months. All patients will be evaluated for safety and effectiveness during Yervoy use (4 doses) and for 12 months from the first dose of Yervoy to confirm the safety profile of Yervoy under routine, daily practice
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Population With Yervoy Exposure
- description
- Population With Yervoy Exposure
Primary outcomes (3)
- measure
- The incidence of adverse events (AEs) by types among the analysis population
- timeFrame
- 12 months
- measure
- The Overall Survival (OS) Rate
- timeFrame
- 12 months
- measure
- The factors that potentially affect safety or effectiveness
- timeFrame
- 12 months
- description
- Stratified analysis on the incidence of adverse events (AEs) and effectiveness by patient background
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All patients who are initiating treatment with Yervoy Exclusion Criteria: * Not Applicable Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available